KR20060007104A - Organic constituents of wood vinegar from konara having the effects of cure and prevention of cancer, antibacterial and antioxidant - Google Patents
Organic constituents of wood vinegar from konara having the effects of cure and prevention of cancer, antibacterial and antioxidant Download PDFInfo
- Publication number
- KR20060007104A KR20060007104A KR1020040055842A KR20040055842A KR20060007104A KR 20060007104 A KR20060007104 A KR 20060007104A KR 1020040055842 A KR1020040055842 A KR 1020040055842A KR 20040055842 A KR20040055842 A KR 20040055842A KR 20060007104 A KR20060007104 A KR 20060007104A
- Authority
- KR
- South Korea
- Prior art keywords
- wood vinegar
- wood
- organic solvent
- layer
- vinegar
- Prior art date
Links
- 239000002023 wood Substances 0.000 title claims abstract description 130
- 239000000052 vinegar Substances 0.000 title claims abstract description 112
- 235000021419 vinegar Nutrition 0.000 title claims abstract description 110
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 33
- 201000011510 cancer Diseases 0.000 title claims abstract description 32
- 230000000694 effects Effects 0.000 title abstract description 28
- 230000003078 antioxidant effect Effects 0.000 title abstract description 12
- 230000000844 anti-bacterial effect Effects 0.000 title abstract description 11
- 230000002265 prevention Effects 0.000 title abstract description 6
- 239000003963 antioxidant agent Substances 0.000 title abstract description 5
- 239000000470 constituent Substances 0.000 title 1
- 239000005416 organic matter Substances 0.000 claims abstract description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000003960 organic solvent Substances 0.000 claims abstract description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000004821 distillation Methods 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 238000000605 extraction Methods 0.000 claims abstract description 8
- 239000012535 impurity Substances 0.000 claims abstract description 8
- 238000009835 boiling Methods 0.000 claims abstract description 7
- 239000000779 smoke Substances 0.000 claims abstract description 7
- 239000007787 solid Substances 0.000 claims abstract description 7
- 238000003763 carbonization Methods 0.000 claims abstract description 6
- 238000001914 filtration Methods 0.000 claims abstract description 6
- 238000000926 separation method Methods 0.000 claims abstract description 5
- 239000000706 filtrate Substances 0.000 claims abstract description 4
- 239000011368 organic material Substances 0.000 claims abstract description 4
- 238000010000 carbonizing Methods 0.000 claims abstract description 3
- 208000006558 Dental Calculus Diseases 0.000 claims abstract 2
- 230000000845 anti-microbial effect Effects 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 230000001093 anti-cancer Effects 0.000 abstract description 18
- 230000002790 anti-mutagenic effect Effects 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 230000035772 mutation Effects 0.000 abstract description 7
- 239000000654 additive Substances 0.000 abstract description 2
- 230000000996 additive effect Effects 0.000 abstract description 2
- 230000000235 effect on cancer Effects 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 20
- 241000894006 Bacteria Species 0.000 description 12
- 239000000243 solution Substances 0.000 description 9
- 230000002292 Radical scavenging effect Effects 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- RAUWPNXIALNKQM-UHFFFAOYSA-N 4-nitro-1,2-phenylenediamine Chemical compound NC1=CC=C([N+]([O-])=O)C=C1N RAUWPNXIALNKQM-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000003859 lipid peroxidation Effects 0.000 description 5
- 239000011269 tar Substances 0.000 description 5
- -1 terpene compounds Chemical class 0.000 description 5
- YHQDZJICGQWFHK-UHFFFAOYSA-N 4-nitroquinoline N-oxide Chemical compound C1=CC=C2C([N+](=O)[O-])=CC=[N+]([O-])C2=C1 YHQDZJICGQWFHK-UHFFFAOYSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 241000186216 Corynebacterium Species 0.000 description 4
- 241000194033 Enterococcus Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000192125 Firmicutes Species 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 241000607142 Salmonella Species 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 229940093499 ethyl acetate Drugs 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 229940118019 malondialdehyde Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000003471 mutagenic agent Substances 0.000 description 4
- 231100000707 mutagenic chemical Toxicity 0.000 description 4
- 230000003505 mutagenic effect Effects 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000588914 Enterobacter Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 3
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003546 flue gas Substances 0.000 description 3
- 239000012676 herbal extract Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 238000010953 Ames test Methods 0.000 description 2
- 231100000039 Ames test Toxicity 0.000 description 2
- 235000017519 Artemisia princeps Nutrition 0.000 description 2
- 244000065027 Artemisia princeps Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 206010016952 Food poisoning Diseases 0.000 description 2
- 208000019331 Foodborne disease Diseases 0.000 description 2
- 240000004580 Magnolia hypoleuca Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 description 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000002072 anti-mutant effect Effects 0.000 description 2
- 230000002019 anti-mutation Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001327284 Sorghastrum nutans Species 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 239000011276 wood tar Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/49—Fagaceae (Beech family), e.g. oak or chestnut
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Abstract
본 발명은 암 치료 및 예방, 항균 및 항산화에 우수한 효과를 갖는 목초액 유기물에 관한 것이다.The present invention relates to woody vinegar organics having an excellent effect on cancer treatment and prevention, antibacterial and antioxidant.
본 발명은 (a) 참나무 칩을 탄화하여 소정의 배연온도에서 연기를 포집하여 목초액을 추출하고, 상기 추출된 목초액에서 고형분과 목타르를 배제하고, 상기 배제된 목초액을 정치하면서 소정의 기간동안 숙성하는 목초액 탄화공정과; (b) 상기 탄화공정을 거친 목초액에서 유해한 저비점성분을 감압증류로 제거하고, 상기 감압증류된 목초액을 흡착 및 여과하여 난분리 불순물을 분리하고 여액의 목초액을 수득하는 목초액 증류공정과; (c) 상기 증류공정을 거친 목초액에 염화메틸렌 또는 에틸아세테이트로부터 선택된 유기용매를 부가한 후 진탕하여 유기용매층과 목초액층을 1차 분리하고, 상기 목초액층에 염화메틸렌 또는 에틸아세테이트로부터 선택된 유기용매를 다시 첨가한 후 진탕하여 유기용매층과 목초액층을 2차 분리하여 상기 1차 및 2차의 유기용매층을 수득하는 목초액 유기물 추출공정; 및 (d) 상기 혼합한 유기용매층에서 유기용매를 제거하는 유기용매 제거공정을 포함하여 이루어진 공정으로부터 수득한 목초액 유기물을 제공한다.The present invention (a) carbonizing oak chips to capture the smoke at a predetermined flue temperature to extract the wood vinegar, excluding the solids and tar tar from the extracted wood vinegar, and aged for a predetermined period of time while leaving the excluded wood vinegar Wood liquor carbonization process; (b) a wood liquor distillation step of removing harmful low-boiling components from the carbonized wood liquor by distillation under reduced pressure, adsorbing and filtering the distilled distilled liquor to separate egg separation impurities, and obtaining wood liquor from the filtrate; (c) adding an organic solvent selected from methylene chloride or ethyl acetate to the wood vinegar, which has been subjected to the distillation, and shaking the mixture to first separate the organic solvent layer and the wood vinegar layer, and to the wood vinegar layer, an organic solvent selected from methylene chloride or ethyl acetate. Adding and then shaking to separate the organic solvent layer and the wood vinegar layer to obtain the first and the second organic solvent layer wood vinegar organic material extraction step; And (d) an organic solvent removing step of removing the organic solvent from the mixed organic solvent layer.
본 발명은 암을 치료하거나 동시에 돌연변이의 억제에 의해 암을 예방할 수 있고, 항균 및 항산화 효과를 활용하여 건강기능 식품에도 첨가물로 사용될 수 있는 효과가 있다.The present invention can prevent cancer by treating cancer or at the same time inhibiting mutations, and has an effect that can be used as an additive in health food by utilizing antibacterial and antioxidant effects.
목초액, 유기물, 항암효과, 항돌연변이효과, 항균효과, 항산화효과Wood vinegar, organic matter, anticancer effect, antimutagenic effect, antibacterial effect, antioxidant effect
Description
도 1은 본 발명에 따른 목초액 유기물의 돌연변이원 MNNG에 대한 항돌연변이 활성을 나타낸 그래프이고, 1 is a graph showing the antimutagenic activity of the mutant MNNG of wood vinegar organic matter according to the present invention,
도 2는 본 발명에 따른 목초액 유기물의 돌연변이원 NQO에 대한 항돌연변이 활성을 나타낸 그래프이고,Figure 2 is a graph showing the antimutagenic activity for mutant NQO of the wood vinegar organic matter according to the present invention,
도 3은 본 발명에 따른 목초액 유기물의 지질과산화 억제효과를 나타낸 그래프이고, 3 is a graph showing the lipid peroxidation inhibitory effect of wood vinegar organics according to the present invention,
도 4는 본 발명에 따른 목초액 유기물의 DPPH 라디칼 소거효과를 나타낸 그래프이다.4 is a graph showing the DPPH radical scavenging effect of the wood vinegar organic matter according to the present invention.
본 발명은 암 치료 및 예방, 항균 및 항산화에 우수한 효과를 갖는 목초액 유기물에 관한 것으로, 보다 상세하게는 목초액을 고순도로 정제한 다음, 정제된 목초액으로부터 유기물을 추출하여 항암 효과가 우수하고, 암의 주요 유발요인인 돌연변이를 억제하는 효과가 우수하고, 다양한 종류의 균주에 대한 항균활성 및 지질과산화 억제효과와 라디칼 소거효과 등을 가진 목초액 유기물을 유효성분으로 하는 약제학적 조성물 또는 건강보조식품에 관한 것이다.The present invention relates to a wood vinegar organic matter having an excellent effect on cancer treatment and prevention, antibacterial and antioxidant, and more particularly, purified wood vinegar in high purity, and then extracted organic matter from the purified wood vinegar solution is excellent anti-cancer effect, The present invention relates to a pharmaceutical composition or a dietary supplement comprising a wood-based organic matter having an excellent effect of inhibiting mutation, which is a major inducing factor, and having an antimicrobial activity against various kinds of strains, an inhibitory effect on lipid peroxidation, and a radical scavenging effect. .
목초액(木酢液)은 통상적으로 참나무를 직접탄화하여 탄화하는 과정에서 나무의 열분해 중합반응에 의하여 발생되는 연기를 포집하여 냉각시키면 응축되는 액체를 조목초액이라 하며 이때 좋은 목초액을 얻기 위하여 탄화온도가 중요하고 배연되는 연기(가스)의 온도가 150℃이하에서 생산한 것이 좋은 것으로 알려져 있다. Wood vinegar is a crude wood vinegar, which collects and cools the smoke generated by the pyrolysis polymerization of wood in the process of directly carbonizing oak wood. The carbonization temperature is important for obtaining good wood vinegar. It is known that the smoke (gas) produced at the temperature of less than 150 ℃ produced.
그리고, 이런 상태의 조목초액을 6개월 이상 숙성 및 정치를 시키면 상층의 경유질, 중층의 목초액, 하층의 타르질의 세층으로 분리되는데, 중층의 물에 녹는 액을 목초액이라 하여 농업용, 산업용 뿐만 아니라 의약품, 건강음료 등으로 많이 이용되고 있다. And, when aged and aged for 6 months or more in this state, the crude oil in the upper layer, middle vinegar in the middle layer, tarryul in the lower layer is divided into three layers of water, soluble in water in the middle layer is called wood vinegar solution for agricultural, industrial as well as pharmaceutical It is widely used for health drinks.
그리고, 보통 목초액의 80∼90%는 물이고, 10∼20%는 유기물이면서 초산을 주요성분으로 하는 산성액체로서, 제조하는 과정에서 독성과 유해물질을 제거한 것이기 때문에 초산의 신맛과 탄내를 풍기는 자극적인 냄새를 갖고 있다. Usually, 80 ~ 90% of wood vinegar is water, and 10 ~ 20% is organic acid and acidic liquid whose main component is acetic acid. It has a smell of phosphorus.
또한, 목초액은 우리나라, 일본, 중국등지에서 민간요법으로 널리 사용되고 있는데, 주로 간보호 효과, 항당뇨 효과, 알코올 해독 효과, 항암 효과등이 있는 것으로 알려져 있으며, 특히 일본에서는 목초액의 용도에 관한 특허가 수백개가 등록되어 있으나 주로 농업용(농약대용, 비료혼합물등)이나 산업용(탈취제, 살균제, 공해물질 분해, 식품첨가제 등)으로 개발되어 있고, 약리효능에 대한 특허는 일부 암세포에 대한 항암효과, 이뇨효과 등에 관한 것이 알려져 있다.In addition, wood vinegar is widely used as a folk remedy in Korea, Japan, China, etc. It is mainly known that it has a liver protection effect, anti-diabetic effect, alcohol detoxification effect, anti-cancer effect, etc. Hundreds are registered, but mainly developed for agriculture (pesticide substitute, fertilizer mixture, etc.) or industrial (deodorant, fungicide, pollutant decomposition, food additives, etc.). Etc. are known.
그리고, 목초액의 항암효과에 관한 연구로는 참나무 목초액의 면역조절 작용과 항암효과에 관한 연구[김동희 등. 목초액과 항암성 본초가 가미된 복합목초액의 항암 및 항전이활성에 미치는 영향. 동의생리병리학회지 2001, 15(1), 136-142]와 수종의 항암성 생약을 목초액으로 추출한 추출물의 항암효과에 관한 연구[김동희 등. 참나무 목초액의 면역조절작용과 항암효과에 관한 연구. 동의생리병리학회지 2001, 15(6), 881∼886]가 공지되어 있다.In addition, studies on the anticancer effect of wood vinegar as a study on the immunomodulatory effect and anticancer effect of oak vinegar [Kim Dong-Hee et al. Effect of Wood Vinegar and Anticancer Herbal Compounds on Anticancer and Antimetastatic Activity. Korean Journal of Oriental Physiology and Pathology 2001, 15 (1), 136-142] and a study on the anticancer effects of extracts from several kinds of anticancer herbal medicines with wood vinegar [Kim, Dong-Hee et al. A Study on the Immunoregulatory and Anticancer Effects of Oak Tree Vinegar The Korean Journal of Oriental Physiology and Pathology 2001, 15 (6), 881-886.
그러나, 현재까지 목초액의 유기물에 대한 다양한 암세포를 이용한 세포독성 연구, 항돌연변이 활성 연구, 항균 및 항산화활성에 관한 연구 등은 알려져 있지 않다.However, until now, there are no known cytotoxicity studies using various cancer cells, antimutagenic activity, antimicrobial activity and antioxidative activity against organic matter of wood vinegar.
그리고, 암은 문명의 발달과 더불어 증가하고 있는 질병중의 하나로, 이를 치료하는 방법으로는 외과적 수술, 방사선 치료, 항암물질 투여에 의한 화학 요법 등이 알려져 있다. 그러나, 상기 치료방법들은 대부분 초기 암환자나 특정암의 치료에만 국한되어 있어 암으로 인한 사망이 꾸준히 증가하고 있고, 특히 방사선 치료법이나 화학 요법은 많은 부작용을 유발하는 등의 문제점이 있다. In addition, cancer is one of diseases increasing with the development of civilization, and methods for treating the same are known as surgical surgery, radiation therapy, chemotherapy by administration of anticancer substances, and the like. However, most of the treatment methods are limited to the treatment of early cancer patients or specific cancers, and death due to cancer is steadily increasing. In particular, radiation therapy or chemotherapy causes many side effects.
따라서, 부작용을 줄이면서 제암율을 높일 수 있는 항암제의 개발이 요구되고 있으며, 그 대안으로 종래 천연물, 특히 생약재로부터 항암제를 개발하려는 시도가 활발히 이루어지고 있다. Therefore, there is a demand for the development of anticancer drugs that can increase anticancer rates while reducing side effects, and as an alternative, attempts have been actively made to develop anticancer drugs from conventional natural products, particularly herbal medicines.
그 실례(實例)로, 단삼(Salvia miltiorrhiza)의 경우, 염화메틸렌 분획에서 분리한 18종의 테르펜류 화합물이 항암효과를 나타내며, 암세포에 따라 약 20∼500 ㎍/㎖정도의 ED50값을 갖는 다는 보고가 있었고(Planta Medica 63, 1997년, Georg Thieme Verlag, 독일, S.Y. Ryu, C.O. Lee, S.U. Choi, In vitro cytotoxicity of tanshinones from Salvia miltiorrhiza, pp. 339-342), 일목련(Magnolia obovata)의 에틸아세테이트 분획에서 분리된 6종의 다양한 구조를 갖는 화합물도 항암효과를 나타내며, 암세포에 따라 12.5~20.2㎍/㎖정도의 ED50값을 갖는다는 보고가 있었다(Planta Medica 65, 1999년, Georg Thieme Verlag, 독일, Y.K. Kim, S.Y. Ryu, Cytotoxic components from stem bark of Magnolia obovata, pp. 291-292).For example, in the case of Salvia miltiorrhiza, 18 terpene compounds isolated from the methylene chloride fraction show anticancer effects, and have ED 50 values of about 20 to 500 ㎍ / ml depending on the cancer cells. (Planta Medica 63, 1997, Georg Thieme Verlag, Germany, SY Ryu, CO Lee, SU Choi, In vitro cytotoxicity of tanshinones from Salvia miltiorrhiza, pp. 339-342), and Magnolia obovata Compounds with six different structures isolated from ethyl acetate fractions also have anti-cancer effects and have been reported to have ED 50 values ranging from 12.5 to 20.2 µg / ml depending on the cancer cells (Planta Medica 65, 1999, Georg Thieme). Verlag, Germany, YK Kim, SY Ryu, Cytotoxic components from stem bark of Magnolia obovata, pp. 291-292).
또한, 아르테미시아 프린셉스(Artemisia princeps)의 염화메틸렌분획에서 분리된 8종의 다양한 구조를 갖는 화합물이 항암효과는 나타내며, 암세포에 따라 28.5~45.8㎍/㎖정도의 ED50값을 갖는 다는 보고가 알려져 있다(Planta Medica 63, 1997년, Georg Thieme Verlag, 독일, S.Y. Ryu, J.O. Kim, S.U. Choi, Cytotoxic components of Artemisia princeps, pp. 384-385).In addition, eight compounds having various structures isolated from methylene chloride fractions of Artemisia princeps showed anti-cancer effects and reported that they had ED 50 values of 28.5 to 45.8 µg / ml depending on cancer cells. (Planta Medica 63, 1997, Georg Thieme Verlag, Germany, SY Ryu, JO Kim, SU Choi, Cytotoxic components of Artemisia princeps, pp. 384-385).
그러나, 상기와 같은 종래의 생약 추출물 항암제들은 생약추출물이기 때문에 부작용을 줄일 수는 있었지만, 항암효과가 약하여 암의 치료에 효과적이지 못하였다. 더구나, 이러한 종래의 생약추출물 항암제의 경우에는 암의 원인인 돌연변이를 억제할 수 있는지에 대한 연구가 이루어지지 않았기 때문에, 이들이 암을 예방할 수 있는지에 대해서는 확인할 수 없었다.However, the conventional herbal extracts such as the anticancer drugs were able to reduce the side effects because they are herbal extracts, but the anticancer effect was weak and not effective in the treatment of cancer. Moreover, in the case of such conventional herbal extract anticancer drugs, no research has been conducted on whether the cancer-causing mutations can be suppressed, and thus, it was not possible to confirm whether they could prevent cancer.
한편, 최근에는 체내에서 산소가 대사과정에 참여한 후 생성되는 유해물질인 활성산소종(reactive oxygen species; ROS)을 안전한 물질로 전환시켜주거나 제거 해주는 항산화제에 대한 관심이 고조되고 있다.On the other hand, in recent years, there is a growing interest in antioxidants that convert or remove reactive oxygen species (ROS), which are harmful substances generated after oxygen participates in metabolic processes, into safe substances.
이는 체내에서 암을 비롯한 각종 성인병, 노화, 파킨슨병, 알츠하이머병 등의 뇌신경질환 및 허혈성 신경손상 등과 같은 병태생리현상의 직접적인 원인으로 활성산소종이 관여하는 것으로 알려져 있기때문이다.This is because active oxygen species are known to be involved as a direct cause of pathophysiology such as cerebral neurological diseases such as cancer, various adult diseases including cancer, aging, Parkinson's disease, Alzheimer's disease and ischemic nerve injury.
한 예로, ROS의 생성과 분해 메카니즘 조절 상실은 과잉의 ROS가 세포막 지방질의 지질과산화를 유도함으로써 생체조직이 손상되어 각종 질환이 발생한다는 사실이 연구로 통해 알려져 있다. For example, it is known from research that loss of regulation of ROS production and degradation mechanism is caused by excessive ROS inducing lipid peroxidation of cell membrane lipids, resulting in damage to biological tissues and various diseases.
따라서, 본 발명자는 상기 성인병, 뇌신경질환 및 병태생리현상 등을 동시에 치료나 예방할 수 있으면서 부작용은 거의 없는 천연 조성물을 찾고자 하였으며, 상기 천연 조성물 중 목초액의 유기물이 폴리페놀 성분을 비롯한 다양한 종류의 유효성분을 함유하고 있다는 것에 착안하여 암을 비롯한 다양한 질환의 예방 및 치료는 물론 항산화물질로도 활용될 수 있을 것으로 판단하였다.Accordingly, the present inventors have tried to find a natural composition that can simultaneously treat or prevent the adult diseases, neurological diseases and pathophysiological phenomena, and has little side effects, and the organic matter of wood vinegar in the natural composition includes various types of active ingredients including polyphenol components. In view of the fact that it contains, it was determined that it can be used as an antioxidant as well as prevention and treatment of various diseases including cancer.
이에, 본 발명자는 상기와 같은 문제점을 해결하기 위하여, 종래 목초액보다 유효성분(폴리페놀 성분등)의 함량 및 종류가 많은 목초액을 제조하기 위해, 종래 목초액의 제조방법과는 다른 방법을 개발하고, 상기 개발된 방법으로 제조한 목초액의 유기성분이 암의 치료 및 예방, 항균 및 항산화 효과에 있어서 탁월하게 우수한 사실을 확인하고자 하였으며, 본 발명의 제조방법에 따른 목초액이 암의 예방 및 치료, 미생물 감염, 그리고 생체 성분의 산화반응에 의한 제반 증상이나 질환을 개선할 수 있는 우수한 효과를 갖는 다는 것을 입증하여, 본 발명을 완성하였다. Thus, in order to solve the problems described above, the present inventors have developed a method different from the conventional method for producing the wood vinegar, in order to produce a wood vinegar containing more content and types of active ingredients (polyphenol components, etc.) than conventional wood vinegar, The organic component of the wood vinegar prepared by the method developed above was to confirm that the excellent excellent in the treatment and prevention of cancer, antibacterial and antioxidant effect, the wood vinegar according to the production method of the present invention prevents and treats cancer, microbial infection, The present invention has been completed by proving that it has an excellent effect of improving various symptoms and diseases caused by oxidation of biological components.
따라서, 본 발명의 목적은 (a) 목초액 탄화공정과; (b) 목초액 증류공정; 및 (c) 목초액 유기물 추출공정으로 이루어진 새로운 목초액의 제조방법을 제공하고, 이로부터 획득한 목초액 유기물을 제공하는 것이다.Accordingly, an object of the present invention is (a) wood grass liquor carbonization process; (b) wood liquor distillation process; And (c) provides a method for producing a new wood vinegar consisting of the wood vinegar organic matter extraction process, to provide a wood vinegar organic matter obtained therefrom.
상기와 같은 목적을 달성하기 위하여, 본 발명은 (a) 참나무 칩을 탄화하여 75∼85℃의 배연온도에서 연기를 포집하여 목초액을 추출하고, 상기 추출된 목초액에서 고형분과 목타르를 배제하고, 상기 배제된 목초액을 정치하면서 6∼12개월 동안 숙성하는 목초액 탄화공정과; (b) 상기 탄화공정을 거친 목초액에서 유해한 저비점성분을 감압증류로 제거하고, 상기 감압증류된 목초액을 흡착 및 여과하여 난분리 불순물을 분리하고 여액의 목초액을 수득하는 목초액 증류공정과; (c) 상기 증류공정을 거친 목초액에 유기용매인 염화메틸렌을 부가한 후 진탕하여 유기용매층과 목초액층을 1차 분리하고, 상기 목초액층에 유기용매인 에틸아세테이트를 다시 첨가한 후 진탕하여 유기용매층과 목초액층을 2차 분리하여 상기 1차 및 2차의 유기용매층을 수득하는 목초액 유기물 추출공정; 및 (d) 상기 수득한 유기용매층에서 유기용매를 제거하는 유기용매 제거공정을 포함하여 이루어진 공정으로부터 수득한 목초액 유기물을 제공한다.In order to achieve the above object, the present invention (a) carbonized oak chips to collect smoke at the flue gas temperature of 75 ~ 85 ℃ extract the wood vinegar, remove the solids and wood tar from the extracted wood vinegar, Wood liquor carbonization step of ripening for 6 to 12 months while leaving the excluded liquor liquor; (b) a wood liquor distillation step of removing harmful low-boiling components from the carbonized wood liquor by distillation under reduced pressure, adsorbing and filtering the distilled distilled liquor to separate egg separation impurities, and obtaining wood liquor from the filtrate; (c) adding methylene chloride, an organic solvent, to the wood vinegar after distillation, followed by shaking to separate the organic solvent layer and the wood vinegar layer, and adding ethyl acetate, the organic solvent, to the wood vinegar layer, followed by shaking. A wood-choice organic matter extraction step of secondly separating the solvent layer and the wood-choice layer to obtain the first and second organic solvent layers; And (d) an organic solvent removal step of removing the organic solvent from the organic solvent layer obtained.
또한, 다른 목적을 달성하기 위하여, 본 발명은 상기 목초액 유기물을 유효성분으로 함유하는 암 예방 및 치료용 약제학적 조성물을 제공한다.In addition, in order to achieve another object, the present invention provides a pharmaceutical composition for preventing and treating cancer, containing the wood vinegar organic matter as an active ingredient.
또한, 또 다른 목적을 달성하기 위하여, 본 발명은 상기 목초액 유기물을 유효성분으로 함유하는 항균용 약제학적 조성물을 제공한다.In addition, in order to achieve another object, the present invention provides a pharmaceutical composition for antimicrobial containing the wood vinegar organic matter as an active ingredient.
더 나아가, 본 발명은 상기 목초액 유기물을 유효성분으로 함유하는 건강보조식품을 제공한다.Furthermore, the present invention provides a dietary supplement containing the wood-based organic matter as an active ingredient.
이하, 본 발명을 상세히 설명하기로 한다.Hereinafter, the present invention will be described in detail.
이때, 사용되는 기술 용어 및 과학 용어에 있어서 다른 정의가 없다면, 이 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 통상적으로 이해하고 있는 의미를 가진다.At this time, if there is no other definition in the technical terms and scientific terms used, it has a meaning commonly understood by those of ordinary skill in the art.
또한, 종래와 동일한 기술적 구성 및 작용에 대한 반복되는 설명은 생략하기로 한다. In addition, repeated description of the same technical configuration and operation as in the prior art will be omitted.
본 발명의 목초액 유기물은 다른 목초액에 함유된 유기성분과 비교하여 암을 치료하고 예방하는 능력과 항균 및 항산화작용에 탁월한 효과를 나타낸다.Compared with the organic components contained in other wood vinegar, the wood vinegar organic matter of the present invention exhibits an excellent effect on antibacterial and antioxidant activity and the ability to treat and prevent cancer.
이는 목초액의 채취 과정에 따라 유효 성분의 차이가 있고 정제 과정에 따라 몸에 해로운 타르나 크레졸 등의 성분 함유량에서도 차이가 나기 때문이다. This is because there is a difference in the active ingredient according to the extraction process of wood vinegar, and also in the content of ingredients such as tar or cresol harmful to the body depending on the purification process.
이를 위해, 본 발명의 목초액 유기물을 수득하기 위한 제조방법은 다음과 같은 공정을 포함하여 이루어진다.To this end, the production method for obtaining the wood vinegar organic matter of the present invention comprises the following steps.
(a) 목초액 탄화공정(a) wood liquor carbonization process
참나무 칩을 탄화하여 소정의 배연온도에서 연기를 포집하여 목초액을 추출하고, 상기 추출된 목초액에서 고형분과 목타르를 배제하고, 상기 배제된 목초액을 정치하면서 소정의 기간동안 숙성한다.The oak chips are carbonized to capture smoke at a predetermined flue temperature, to extract wood vinegar, to remove solids and tar from the extracted wood vinegar, and aged for a predetermined period of time while leaving the removed wood vinegar.
이때, 상기 배연온도가 75∼85℃에서 목초액을 추출하는 것이 바람직한 데, 이는 75℃ 미만인 경우에는 목초액에 타르, 메탄올, 페놀 등의 독성 함량이 높아지 고, 85℃을 초과할 경우에는 유효성분이 저감될 수 있기때문이다.At this time, it is preferable to extract the wood vinegar at the flue gas temperature of 75 ~ 85 ℃, which is less than 75 ℃ when the toxic content of tar, methanol, phenol, etc. in the wood vinegar is increased, the effective ingredient is reduced when it exceeds 85 ℃ Because it can be.
또한, 추출된 목초액에 남은 유해 불순물을 침전하기 위해 정치하면서 6∼12 개월 동안 숙성하는 것이 바람직한 데, 이는 대량생산으로 인한 불순물 제거비용을 절감할 수 있고, 6 개월 미만으로 숙성을 하면 불순물을 침전시켜 충분히 제거하기가 어렵고, 12 개월을 초과하면 초과 기간에 비하여 숙성 효율에 차이가 없기때문이다.In addition, it is desirable to ripen for 6 to 12 months while standing in order to precipitate the remaining harmful impurities in the extracted wood vinegar, which can reduce the cost of removing impurities due to mass production, and when aged less than 6 months to precipitate impurities It is difficult to remove it sufficiently, and if it exceeds 12 months, there is no difference in aging efficiency compared to the excess period.
(b) 목초액 증류공정(b) wood liquor distillation process
상기 (a) 공정을 거친 목초액에서 유해한 저비점성분을 감압증류로 제거한 후, 상기 감압증류된 목초액을 흡착 및 여과하여 난분리 불순물을 분리한 다음, 여액의 목초액을 수득하는 공정이다.After removing the harmful low boiling point component from the wood vinegar, which has been subjected to the step (a) by distillation under reduced pressure, the vacuum distilled wood vinegar is adsorbed and filtered to separate the egg separation impurities, and then the wood vinegar of the filtrate is obtained.
이때, 상기 감압증류는 -752mmHg의 압력하에 40∼60℃의 온도에서 증류하는 것이 바람직한 데, 이는 40℃ 미만에서는 목초액에 소량으로 함유된 저비점성분인 타르, 메탄올, 페놀을 충분히 제거하기 못하고, 60℃를 초과하면 초과된 온도에 비하여 저비점성분의 제거효율 차이가 거의 없기 때문이다. At this time, the distillation under reduced pressure is preferably distilled at a temperature of 40 ~ 60 ℃ under a pressure of -752mmHg, which is less than 40 ℃ to remove enough low-boiling components of tar, methanol, phenol contained in a small amount in wood vinegar, 60 It is because there is almost no difference in removal efficiency of the low boiling point components when the temperature is exceeded.
또한, 보다 고도로 저비점성분을 제거하기 위해, 상기 감압증류와 흡착 및 여과하는 공정을 한번 이상 더 수행할 수 있다.In addition, in order to more highly remove the low boiling point component, the vacuum distillation, adsorption, and filtration may be performed one or more times.
(c) 목초액 유기물 추출공정(c) Wood Vinegar Organic Extraction Process
상기 (b) 공정을 거친 목초액에 유기용매인 염화메틸렌을 부가한 후 진탕하여 유기용매층과 목초액층을 1차 분리하고, 상기 목초액층에 유기용매인 에틸아세테이트를 다시 첨가한 후 진탕하여 유기용매층과 목초액층을 2차 분리하여 상기 1 차 및 2차의 유기용매층을 수득한다.After adding the methylene chloride as an organic solvent to the wood vinegar after the step (b), the organic solvent layer and the wood vinegar layer are separated by primary shaking, and the ethyl acetate, which is an organic solvent, is added to the wood vinegar layer, followed by shaking. Separation of the second layer and the wood vinegar layer to obtain the organic solvent layer of the primary and secondary.
이의 공정은 목초액에 있는 유기물을 유기용매층에 용해시켜 농축한 다음, 추출하여 유효성분의 종류와 양을 극대화하기 위한 공정으로, 목초액과 유기용매의 혼합비율은 2:1∼3:1로 하여 분리·농축하는 것이 바람직하다. 이는 유기용매 사용량이 목초액에 비하여 1/3 미만이 되면 유기용매층에 충분히 목초액의 유기물을 용해시키지 못하며, 1/2을 초과하게 되면 유기용매의 사용량이 증가하여 추출비용이 상승하고, 상승된 비용에 비하여 추출효과가 미미하기 때문이다.This process is to maximize the type and amount of the active ingredient by dissolving the organic matter in the wood vinegar in an organic solvent layer and then extracted, the mixing ratio of wood vinegar and organic solvent is 2: 1 to 3: 1 It is preferable to isolate and concentrate. This means that when the amount of organic solvent used is less than one third of the amount of wood vinegar, the organic matter of wood vinegar is not sufficiently dissolved in the organic solvent layer. When the amount of the organic solvent is more than half, the amount of the organic solvent is increased and the extraction cost is increased. This is because the extraction effect is insignificant.
(d) 유기용매 제거 공정(d) organic solvent removal process
상기 (c) 공정을 거친 유기용매층에서 유기용매를 제거한다.The organic solvent is removed from the organic solvent layer subjected to the step (c).
이때, 유기용매를 제거하기 위해 감압농축방식을 사용하는 것이 바람직하다.At this time, it is preferable to use a reduced pressure concentration method to remove the organic solvent.
이와같이, 상기 (a), (b), (c), (d) 공정을 거쳐 수득한 목초액 유기물을 본 발명의 목초액 유기물로 사용한다.In this way, the wood vinegar organics obtained through the steps (a), (b), (c) and (d) are used as the wood vinegar organics of the present invention.
한편, 본 발명의 목초액 유기물은 in vitro 실험결과, 100 ㎍/㎖의 농도에서는 모든 암세포의 생장을 완전히 억제하였으며 특히, 흑색종에 대해서는 30 ㎍/㎖의 농도에서도 암세포를 완전히 억제한다.On the other hand, the wood vinegar organic compounds of the present invention as a result of in vitro experiments completely inhibited the growth of all cancer cells at a concentration of 100 ㎍ / ㎖, in particular, melanoma completely inhibits the cancer cells even at a concentration of 30 ㎍ / ㎖.
또한, 본 발명의 목초액 유기물은 직접돌연변이 유발원인 NPD(4-nitro-o-phenylenediamine)에 대해서는 목초액 유기성분이 1 ㎎/플레이트의 농도에서 86.9%의 항 돌연변이 활성을 나타내고, 다른 돌연변이원인 NaN3(sodium azide)에 대해서는 78.8%의 항 돌연변이 활성을 나타내면서, SOS 크로모테스트에서는 β-갈락톡시 다아제 활성을 알카리성 포스파타아제 활성으로 나눈 결과, 낮은 효소활성 비율값을 유지하여 암을 예방한다.In addition, the wood vinegar organic matter of the present invention showed 86.9% of the antimutagenic activity at the concentration of 1 mg / plate of the wood vinegar organic component to NPD (4-nitro- o- phenylenediamine) which is a direct mutagenesis, NaN 3 (sodium) azide) showed 78.8% anti-mutant activity, while SOS chromotest divides β-galactoxylase activity by alkaline phosphatase activity and maintains a low enzyme activity ratio to prevent cancer.
그리고, 본 발명의 목초액 유기물은 그람 양성균과 그람 음성균 모두에 항균성을 가지는데, 실험결과 그람 양성균 중에서는 특히 바실러스 속의 균주들에 높은 항균효과를 가지고, 유산균(젖산균)에는 항균효과를 가지고 있지 않아 생체 내에서 유효한 균에 대해서는 항균활성이 없는 특성을 갖고 있다.In addition, the wood-based organic matter of the present invention has antimicrobial activity to both Gram-positive bacteria and Gram-negative bacteria, and as a result of the experiment, Gram-positive bacteria have a high antimicrobial effect, especially to strains of the genus Bacillus, and do not have an antimicrobial effect to lactic acid bacteria (lactic acid bacteria) The microorganisms effective in the organism have no antimicrobial activity.
또한, 그람 양성균 중 포유동물의 피부나 점막에 감염을 일으키는 코리네박테리움(Corynebacterium)과 그람 음성균들 중에서 식중독이나 장염의 원인이 되는 살모넬라(Salmonella), 엔테로코커스(Enterococcus), 엔테로박터(Enterobacter), 대장균( E. coli)에 항균성을 나타낸다.In addition, gram Corynebacterium salmonella which can cause food poisoning or enteritis among (Corynebacterium) and gram-negative bacteria (Salmonella) causing the infection in the skin or mucous membrane of a mammal of the positive bacteria, Enterococcus (Enterococcus), Enterobacter (Enterobacter) , Antibacterial to E. coli .
그리고, 본 발명의 목초액 유기물은 생체 조직내에서 과산화지질 생성을 크게 억제하고, DPPH(1,1-diphenyl-2-picrylhydrazyl)라디칼을 0.1mg/㎖, 0.5mg/㎖, 1.0mg/㎖의 농도에서 각각 35.6%, 68.8%, 82.4%의 라디칼 소거효과를 가지고 있어 항산화제의 특성을 가진다.In addition, the wood vinegar organic matter of the present invention greatly suppresses the formation of lipid peroxide in the living tissue, the concentration of 0.1mg / ㎖, 0.5mg / ㎖, 1.0mg / ㎖ DPPH (1,1-diphenyl-2-picrylhydrazyl) radicals Have 35.6%, 68.8%, and 82.4% radical scavenging effect, respectively, and have antioxidant properties.
따라서, 본 발명에 따라 제조된 암 예방 및 치료와 항균용 약제학적 조성물과 건강 보조 식품 제조 및 개발에 유용하게 응용하여 사용할 수 있다.Therefore, the present invention can be usefully used for the prevention and treatment of cancer and the antimicrobial pharmaceutical composition and health supplement prepared and developed according to the present invention.
보다 구체적으로는 본 발명의 목초액 유기물을 유효성분으로 한 의약품이나 건강보조식품은 어떠한 제형으로 제조하여도 무방하나, 구체적으로 상기 형태는 정제, 캡슐, 분말, 연고, 용액, 젤, 페이스트, 과립상으로 제조할 수 있다.More specifically, medicines or health supplements containing the wood-based organic matter of the present invention as an active ingredient may be prepared in any dosage form. Specifically, the form may be in the form of tablets, capsules, powders, ointments, solutions, gels, pastes, granules. It can be prepared by.
그리고, 본 발명에 따른 목초액 유기물의 유효량은 통상적으로 하루에 체중 1㎏당 0.1∼0.3 ㎎[0.1∼0.3 ㎎/㎏/일(day)]을 복용하는 것이 바람직하고, 더 바람직하게 0.2 ㎎/㎏/일이 복용되도록 한다. 그러나 실제 투여량은 경구 투여 형태, 환자의 연령, 성별, 체중 및 환자의 중증도 등의 여러 관련 인자에 비추어 결정되어야 하는 것으로 이해되어야 하며, 따라서 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.In addition, the effective amount of the wood vinegar organic matter according to the present invention is usually preferably taken 0.1 to 0.3 mg [0.1 to 0.3 mg / kg / day] per 1 kg body weight per day, more preferably 0.2 mg / kg / Day is to be taken. However, it is to be understood that the actual dosage should be determined in light of several related factors such as oral dosage form, age, sex, weight of the patient and severity of the patient, and therefore the dosage should in any way limit the scope of the invention. It is not.
또한, 상기 범위 내로 제형에 따라 투여하기 위해, 당업자에게 이미 주지되어 있으며 당업자가 용이하게 선정할 수 있는 각종의 부형제, 담체, 또는 희석제 등을 더 포함하여 제조할 수 있다.In addition, to administer according to the formulation within the above range, it can be prepared by further comprising a variety of excipients, carriers, diluents and the like that are well known to those skilled in the art and can be easily selected by those skilled in the art.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명한다. 이들 실시예는 오로지 본 발명을 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 국한되지 않는다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention in detail, and the scope of the present invention is not limited to these examples.
[실시예] 본 발명에 따른 목초액 유기물의 제조EXAMPLES Preparation of Wood Vinegar Organics According to the Present Invention
참나무 칩을 가마에 넣고 가마 온도 350∼400℃ 온도에서 탄화시키면서 배연온도 75∼85℃의 범위 내에서 연기를 포집하여 목초액을 추출하고, 상기 추출된 목초액에서 육안으로 보이는 고형분과 타르를 배제한 다음. 정치하면서 약 6개월 동안 숙성하였다.The oak chips are put in a kiln and carbonized at a kiln temperature of 350-400 ° C. while collecting smoke within the range of flue gas 75-85 ° C. to extract wood vinegar, and the solids and tar visible to the naked eye are removed from the extracted wood vinegar. Aged for about 6 months while standing.
그리고, 침전된 불순물을 제외한 목초액을 -752mmHg의 압력하의 40∼60℃에서 감암증류를 실시하였으며, 상기 감암증류하고 남은 목초액은 거름종이 (Whatman 2)로 흡착 및 여과하였다.Then, the wood vinegar except for the precipitated impurities was subjected to dark distillation at 40-60 ° C. under a pressure of −752 mmHg, and the remaining wooden vinegar was adsorbed and filtered with filter paper (Whatman 2).
그리고, 상기 감압증류, 흡착 및 여과방법을 한번 더 수행하였다.Then, the vacuum distillation, adsorption and filtration were performed once more.
그런다음, 상기 정제된 고순도 목초액 1 ℓ에 염화메틸렌 500 ㎖를 가하고, 분별깔대기에 넣은 다음, 10회 강하게 진탕하고, 1시간 방치하여 두층이 생기게 한 다음, 상층의 수층(목초액층)과 하층의 염화메틸렌층을 분리하였다. 그리고, 염화메틸렌층을 회전식농축기로 감압농축하여 염화메틸렌을 제거하여 염화메틸렌 가용성 유기물을 획득하였다. Then, 500 ml of methylene chloride was added to 1 L of the purified high-purity wood vinegar, and placed in a separatory funnel, followed by strong shaking 10 times, and left for 1 hour to give two layers, followed by the upper aqueous layer (wood herb layer) and the lower layer. The methylene chloride layer was separated. The methylene chloride layer was concentrated under reduced pressure with a rotary concentrator to remove methylene chloride to obtain methylene chloride soluble organics.
또한, 상기 수층에 에틸아세테이트를 부가한다는 것을 제외하고 상기와 동일한 방법으로 수행하여 에틸아세테이트 가용성 유기물을 획득하였다.In addition, ethylacetate soluble organics were obtained in the same manner as above except that ethyl acetate was added to the aqueous layer.
그리고, 상기 두 유기용매에서 획득한 유기물을 혼합하여 본 발명의 목초액 유기물을 완성하였다.Then, the organic matter obtained from the two organic solvents were mixed to complete the wood vinegar organic matter of the present invention.
[실험예 1] 항암효과 측정Experimental Example 1 Anticancer Effect Measurement
암세포주(cell line)는 한국화학연구원에서 배양중인 세포주를 사용하였으며, 세포배양은 온도 37℃, 습도 100%, CO2농도 10%를 유지하였다. 상기 실시예 유기물(이하 시료) 투여 전일 24-웰 플레이트에 혈청 10%를 함유하는 D-MEM(풀 네임)을 각웰마다 1.0㎖씩 넣은 다음, 배양중의 세포를 트립신처리하여 수확하여, 세포계수기(cell counter)로 세포농도를 계산하였다. 그리고, D-MEM으로 농도별로 희석하여 세포수를 달리하여 각각의 웰에 플레이팅하였다. 세포 플레이팅 18시간 후, 배지를 빨아내어 버린 후, 혈청을 함유하지 않는 D-MEM을 웰당 1.0㎖씩 넣고, 시료를 혈청을 함유하지 않는 D-MEM으로 농도별로 희석하여 각 웰에 투여하였다. 투여 4시간 후, 배지를 모두 제거한 뒤, 다시 혈청 10%를 함유하는 D-MEM을 웰당 2.0㎖ 씩 넣었다. 그리고, 시료투여 6일 후, 배지를 모두 제거하고 크리스탈 바이올렛 (crystal violet)으로 3분간 염색하여 건조시킨 후, 해부현미경으로 관찰하여 콜로니 수를 플레이팅한 세포수와 비교하여 암세포의 생존율을 계산하였다. 그 결과를 표 1에 나타내었다. The cancer cell line was used as a cell line in culture at the Korea Research Institute of Chemical Technology, and the cell culture was maintained at 37 ° C., 100% humidity, and 10% CO 2 concentration. Example In the day before administration of the organic material (hereinafter referred to as sample), the D-MEM (full name) containing 10% of serum was added to each well of 1.0 ml in a 24-well plate, and the cells in the culture were trypsinized and harvested. Cell concentration was calculated with a cell counter. Then, the cells were diluted in concentrations by D-MEM and plated in each well by varying the number of cells. After 18 hours of cell plating, the medium was aspirated, and then 1.0 mL of D-MEM containing no serum was added to each well, and the sample was diluted by concentration with D-MEM containing no serum and administered to each well. After 4 hours of administration, all of the medium was removed, and then 2.0 mL of D-MEM containing 10% of serum was added thereto. After 6 days of sample administration, all of the medium was removed, stained with crystal violet for 3 minutes, dried, and observed under an anatomical microscope to compare the number of colonies with the number of plated cells. . The results are shown in Table 1.
상기 표 1로부터, 본 발명의 목초액 유기물은 인체 암세포에 대한 항암 효과가 우수하다는 것을 알 수 있다. 즉, 100 ㎍/㎖의 농도에서는 모든 암세포의 생장을 완전히 억제하였으며 특히, 흑색종에 대해서는 30 ㎍/㎖의 농도에서도 암세포를 완전히 억제하는 것을 알 수 있었다.From Table 1, it can be seen that the wood vinegar organic compound of the present invention has an excellent anticancer effect on human cancer cells. In other words, the growth of all cancer cells was completely inhibited at a concentration of 100 ㎍ / ㎖, in particular, melanoma was found to completely inhibit the cancer cells even at a concentration of 30 ㎍ / ㎖.
[실험예 2] 항 돌연변이 효과 측정Experimental Example 2 Anti-mutation Effect Measurement
2-1. 에임스 시험(Ames test)2-1. Ames test
히스티딘 요구성 돌연변이체인 살모넬라 티피뮤리움(Salmonella typhimurium) TA100과 TA98[한국과학기술원 생명공학 연구소의 유전자 은행 (Korea Collection for Type Cultures)에서 분양 받은 것을 계대 배양한 것]를 사용하여 시험하였다. 음성 대조군으로는 시료를 녹인 용매인 DMSO를 사용했고, 양성대조군 으로는 돌연변이원인 NPD(4-nitro-o-phenylenediamine)와 NaN3(sodium azide)를 사용하여 돌연 변이율을 상호 비교하였다. The histidine-required mutants Salmonella typhimurium TA100 and TA98 [passage cultured from Korea Collection for Type Cultures of the Institute of Biotechnology, Korea Advanced Institute of Science and Technology] were tested. As a negative control, DMSO, a solvent in which a sample was dissolved, was used. As a positive control, mutation rates were compared using a mutagen NPD (4-nitro- o- phenylenediamine) and NaN 3 (sodium azide).
한편, 실험전에 상기 균주들은 정기적으로 히스티딘 요구성, deep rough character, UV 감수성 및 R 요소(R factor) 존재 등의 유전형질을 확인한 후 시험 균주로 사용하였다. Meanwhile, before the experiment, the strains were regularly used as test strains after confirming genotypes such as histidine requirement, deep rough character, UV sensitivity, and R factor.
항 돌연변이 실험을 위한 배지, 필요한 시약의 조제는 마론(Maron)과 에임스(Ames)의 방법에 따라 수행하였다. The medium for anti-mutation experiments and the preparation of the necessary reagents were performed according to the method of Maron and Ames.
즉, 하루밤 배양된 균주(1∼2×109 cells/㎖) 0.1㎖, 돌연변이원0.1㎖ (NPD는 10㎍, NaN3는 1㎍ 함유), 인산나트륨 완충액 0.5㎖와 상기 실시예의 목초액 유기물를 1㎎/플레이트의 농도로 시험관에 첨가한 후, 가볍게 와류시키고, 37℃에서 20분 동안 예비 배양하였다. 그리고, 45℃에 보관중이던 탑 아가(top agar) 2㎖씩을 각각 튜브에 붓고, 3초간 와류시킨 후, 최소 글루코스 아가 플레이트(minimal glucose agar plate)에 도말한 다음, 37℃에서 48시간 동안 배양하고, 복귀돌연변이수를 계수하였다. That is, 0.1 ml of the strain cultured overnight (1-2 × 10 9 cells / ml), 0.1 ml of mutagen (containing 10 µg of NPD, 1 µg of NaN 3 ), 0.5 ml of sodium phosphate buffer and the wood-vinegar organic matter of the example 1 After addition to the test tube at the concentration of mg / plate, it was lightly vortexed and preincubated for 20 minutes at 37 ℃. Then, 2 ml of top agar stored at 45 ° C. were poured into tubes, vortexed for 3 seconds, plated on minimal glucose agar plate, and incubated at 37 ° C. for 48 hours. The number of return mutations was counted.
이의 결과, 표 2에 나타난 바와 같이, 살모넬라 티피뮤리움 TA98에서 돌연변이원 NPD에 대한 본 발명에 따른 목초액 유기물은 1 ㎎/플레이트의 농도에서 86.9%의 항돌연변이 활성을 나타내었다.As a result, as shown in Table 2, the wood vinegar organic matter according to the present invention for the mutagenic NPD in Salmonella typhimurium TA98 showed an antimutagenic activity of 86.9% at a concentration of 1 mg / plate.
또한, 표 3에 나타난 바와 같이, 살모넬라 티피뮤리움 TA100에서 돌연변이원 NaN3에 대한 본 발명에 따른 목초액 유기물은 78.8%의 항 돌연변이 활성을 나타내었다.In addition, as shown in Table 3, the herbaceous organic matter according to the present invention for the mutant NaN 3 in Salmonella typhimurium TA100 showed 78.8% anti-mutant activity.
2-2. SOS 크로모테스트(Chromotest)2-2. SOS Chromotest
실험예 2-1의 목초액 유기물의 항돌연변이 효과를 보다 확실히 확인하기 위하여, MNNG (N-methyl-N'-nitrosoguadine)와 NQO (4-nitroquinoline-1-oxide)를 돌연변이원으로 하여 SOS 크로모테스트를 하기와 같은 방법으로 실시하였다.SOS chromotest using MNNG (N-methyl-N'-nitrosoguadine) and NQO (4-nitroquinoline-1-oxide) as mutagens to more clearly confirm the antimutagenic effect of the wood-choice organic matter of Experimental Example 2-1 Was carried out in the following manner.
먼저, 배양된 0.5㎖의 E.coli PQ37(실험실에 보관중인 균을 계대 배양한 것)을 50㎖의 리리아 베라타니 배지(Liria Bertani; 트립톤 10g, 효모 추출물 5g, NaCl 10g, 증류수 1.0ℓ, pH 7.0)에 접종하여 37℃에서 4시간 동안 진탕배양하였다 (O.D=0.4∼0.8). 그리고, 상기 배양액 600㎕, 돌연변이원(MNNG, NQO) 20㎕(1㎍/assay) 및 본 발명의 목초액 유기물 10㎕(100㎍/assay)를 시험관에 넣어 SOS반응 을 유도하였다. 37℃에서 2시간 동안 정치한 후, 알카리성 포스파타아제 효소활성을 측정하였다. First, 50 ml of E. coli PQ37 (passage cultured in the laboratory) was cultured and 50 ml of Liria Bertani medium (10 g of tryptone, 5 g of yeast extract, 10 g of NaCl, 1.0 l of distilled water). pH 7.0) was incubated for 4 hours at 37 ℃ (OD = 0.4 ~ 0.8). In addition, 600 μl of the culture solution, 20 μl of mutagen (MNNG, NQO) (1 μg / assay) and 10 μl (100 μg / assay) of the wood vinegar organic matter of the present invention were put into a test tube to induce an SOS reaction. After standing at 37 ° C. for 2 hours, alkaline phosphatase enzyme activity was measured.
그리고, β-갈락톡시다아제 활성은 1.8㎖의 B 완충액(조성: Na2HPO4 5.5g, KCl 0.75g, MgSO4 0.25g, SDS 1.0g, β-머캅토에탄올 2.7㎖, 증류수 1,000㎖, pH 7.0)을 넣어, 37℃에서 5분간 정치하여 온도를 균일화시킨 다음, 0.4㎖의 o-니트로페닐-β-갈락톡시다아제(이하, ONGP) 용액을 첨가하여 10분간 발색을 유지하였다. 1.4㎖의 2.0M Na2CO3용액을 첨가하여 반응을 시킨 후, 420nm에서의 흡광도를 측정하였다. In addition, β-galactoxytase activity was 1.8 ml of B buffer (composition: Na 2 HPO 4 5.5 g, KCl 0.75 g, MgSO 4 0.25 g, SDS 1.0 g, β-mercaptoethanol 2.7 ml, distilled water 1,000 ml, pH 7.0) was added, and the mixture was allowed to stand at 37 DEG C for 5 minutes to uniform the temperature. Then, 0.4 ml of o -nitrophenyl-β-galactoxytase (hereinafter referred to as ONGP) solution was added to maintain color development for 10 minutes. After reacting by adding 1.4 ml of 2.0 M Na 2 CO 3 solution, the absorbance at 420 nm was measured.
알카리성 포스파타아제 활성은 B 완충액 대신 P 완충액(조성: tris-base 121 g, SDS 1.0g, 증류수 1,000㎖, pH 8.8)을, ONGP 용액 대신에 p-니트로페닐-포스포갈락톡시다아제 활성을 측정하였다. 효소반응의 정지를 위하여 0.7㎖의 2.5M HCl를 첨가한 후 5분간 반응을 정지하고, 0.7㎖의 2.0M Tris-HCl 완충액를 첨가하였다. Alkaline phosphatase activity was measured using P buffer (composition: tris-base 121 g, SDS 1.0 g, distilled water 1,000 mL, pH 8.8) instead of B buffer, and measuring p-nitrophenyl-phosphogalactoxidase activity instead of ONGP solution. It was. To stop the enzymatic reaction, 0.7 ml of 2.5M HCl was added and then the reaction was stopped for 5 minutes, and 0.7 ml of 2.0M Tris-HCl buffer was added.
각 효소의 활성은 「1000×A420/t」의 식을 사용하여 측정하였고(식중, A420은 420nm에서의 흡광도를, t는 반응시간(분)을 나타낸다), 효소활성 비율(induction factor)은 β-갈락톡시다아제 활성을 알카리성 포스파타아제 활성으로 나누어 계산하였다. The activity of each enzyme was measured using the formula of 1000 × A 420 / t (wherein A 420 represents the absorbance at 420 nm and t represents the reaction time in minutes). Was calculated by dividing β-galactoxytase activity by alkaline phosphatase activity.
이의 결과, 도 1과 도 2에 도시된 바와 같이, 상기 에임스 시험과 동일하게 본 발명에 따른 목초액 유기물이 낮은 효소활성 비율값을 나타내었으며, 이의 사실로 본 발명의 목초액 유기물이 돌연변이를 효과적으로 억제하므로써 암의 예방효과 가 매우 우수하다는 것을 알 수 있었다.As a result, as shown in Figures 1 and 2, the same as the Ames test, wood herb organics according to the present invention showed a low enzyme activity ratio value, the fact that the wood herb organics of the present invention by effectively inhibiting mutations The preventive effect of cancer was very good.
[실험예 3] 항균 효과 측정Experimental Example 3 Antibacterial Effect Measurement
항균효과 측정을 위한 지시균들을 해당하는 액체배지에서 하룻밤 배양한 후 각각 동일한 고체배지에 도말하였다. 이 고체배지 위에 직경 6 mm 가량의 구멍을 여러개 뚫고 여기에 본 발명의 목초액 유기물(1mg/㎖)을 50 ㎕ 넣고 4℃에서 2시간 가량 방치한 후 각 균들의 최적성장온도에서 하룻밤 배양하였다. 그 결과 구멍 주위에 생긴 성장억제환 (clear zone)의 크기를 측정하여 항균정도를 판단하였다. 실험에 사용한 균주는 총 48종를 사용하였다. Indicator bacteria for measuring the antimicrobial effect were incubated overnight in the corresponding liquid medium and then plated on the same solid medium. Several holes with a diameter of about 6 mm were drilled on the solid medium, and 50 μl of the wood vinegar organic matter (1 mg / ml) of the present invention was added thereto and left at 4 ° C. for 2 hours, followed by incubation overnight at the optimum growth temperature of the bacteria. As a result, the degree of antimicrobial activity was determined by measuring the size of the growth zone around the hole. A total of 48 strains were used for the experiment.
이의 결과, 하기 표 4에 나타난 바와 같이, 본 발명의 목초액 유기물은 그람 양성균과 그람 음성균 모두에 항균효과를 나타내었다. 그람 양성균들 중에서는 특히 바실러스(Bacillus) 속의 균주들에 높은 항균효과를 나타내었으나 유산균(젖산균)에는 항균효과를 나타내지 않았다. 따라서 목초액을 복용할 경우 우리 몸의 유산균에는 영향을 주지 않을 것으로 사료된다. 또한 그람 양성균 중 포유동물의 피부나 점막에 감염을 일으키는 코리네박테리움 (Corynebacterium)에 높은 항균 효과를 나타내었으며, 그람 음성균들 중에서는 식중독이나 장염의 원인이 되는 살모넬라(Salmonella),엔테로코커스(Enterococcus), 엔테로박터(Enterobacter), 대장균에 항균효과를 나타내었다.As a result, as shown in Table 4, the wood vinegar organic matter of the present invention showed an antimicrobial effect on both Gram-positive bacteria and Gram-negative bacteria. Among the Gram-positive bacteria, the strains of Bacillus genus showed high antibacterial effect, but not to lactic acid bacteria (lactic acid bacteria). Therefore, taking wood vinegar does not affect the body's lactobacillus. Also it exhibited a high antimicrobial activity on Gram Corynebacterium (Corynebacterium) causing the infection in the skin or mucous membrane of a mammal of the positive bacteria, gram-negative bacteria from among the Salmonella that cause food poisoning or enteritis (Salmonella), Enterococcus (Enterococcus ), Enterobacter, and E. coli showed antimicrobial effects.
[실험예 4] 항산화효과 측정Experimental Example 4 Antioxidant Effect Measurement
4-1. 지질과산화 억제효과4-1. Lipid Peroxidation Inhibitory Effect
과산화지질 함량 측정은 오카와(Ohkawa) 등의 방법에 준해 동물의 뇌조직 마쇄균질액 0.1㎖와 시료 0.05 ㎖을 0.1M 포타슘포스페이트 완충액 (pH 7.4) 0.65㎖에 혼합하고 37℃에서 1시간 배양한 다음, 여기에 8.1% 소듐도데실설페이트 0.2㎖, 20% 아세테이트 완충액 (pH 3.5) 1.5㎖ 및 0.8% 2-티오바르비투르산 용액 1.5㎖을 가해 95℃에서 다시 1시간동안 반응시킨다. 이 혼액을 실온으로 냉각한 다음, 생성된 홍색의 착색물질을 n-부탄올 : 피리딘 (15:1, v/v) 혼액으로 이행시켜 3,000rpm에서 10분간 원심분리하고 그 상징액을 파장 532nm에서 흡광도의 변화를 측정하여 정량하였다. 과산화지질의 함량은 조직 1g당 말론디알데히드(MDA)의 양을 나노몰 (nmole)로 나타낸다.To measure the lipid peroxide content, 0.1 ml of brain tissue homogenate and 0.05 ml of sample were mixed with 0.65 ml of 0.1 M potassium phosphate buffer (pH 7.4) according to the method of Okawa et al. To this, 0.2 ml of 8.1% sodium dodecyl sulfate, 1.5 ml of 20% acetate buffer (pH 3.5) and 1.5 ml of 0.8% 2-thiobarbituric acid solution were added and reacted again at 95 ° C for 1 hour. The mixture was cooled to room temperature, and the resulting red colored material was transferred to an n -butanol: pyridine (15: 1, v / v) mixture, centrifuged at 3,000 rpm for 10 minutes, and the supernatant was absorbed at wavelength 532 nm. Changes were measured and quantified. Lipid peroxide content is the amount of malondialdehyde (MDA) per gram of tissue in nanomoles (nmole).
그리고, 본 발명의 목초액 유기물이 세포에서의 지질과산화 반응을 어느 정도 억제하는지를 in vitro에서 관찰한 결과, 도 3에 나타난 바와같이. 뇌조직에서대조군의 22.5 MDA nmoles/g(조직 1g 당 MDA의 나노몰)에 비해, 본 발명의 유기물은 0.1mg/㎖, 0.5mg/㎖, 1.0mg/㎖의 농도에서 각각 21.9, 10.4, 4.5 nmoles/g로 나타났다. In addition, as a result of observing in vitro how much the wood-vinegar organic matter of the present invention inhibits lipid peroxidation reaction in cells, as shown in FIG. 3. Compared to 22.5 MDA nmoles / g of control (nanomol of MDA per gram of tissue) in the brain tissue, the organics of the present invention were 21.9, 10.4, and 4.5 at concentrations of 0.1 mg / ml, 0.5 mg / ml and 1.0 mg / ml, respectively. nmoles / g.
이로부터, 본 발명의 목초액 유기물은 용량의존적으로 뇌조식과 간 조직에서 과산화지질의 생성을 크게 억제하는 것을 알 수 있었다.From this, it can be seen that the wood vinegar organic matter of the present invention greatly inhibits the production of lipid peroxide in brain breakfast and liver tissue in a dose-dependent manner.
4-2. DPPH 라디칼 소거효과4-2. DPPH radical scavenging effect
DPPH(1,1-diphenyl-2-picrylhydrazyl) 라디칼의 함량 측정은 Blosi의 방법에 따라 시료를 농도별로 하여 목초액 유기성분 0.1㎖에 DPPH radical의 1.5x10-5M 에탄올 용액 4㎖을 첨가하여 실온에서 30분간 반응시킨 다음, 520nm에서 흡광도를 측정하여 산출한다. DPPH 라디칼의 소거활성(Radical scavenging activity)은 다음 식으로 산정하였다.The content of DPPH (1,1-diphenyl-2-picrylhydrazyl) radical was measured according to the method of Blosi, and 4 ml of 1.5x10 -5 M ethanol solution of DPPH radical was added to 0.1 ml of organic component of wood vinegar at room temperature. After reacting for 30 minutes, absorbance at 520 nm is measured and calculated. Radical scavenging activity of DPPH radical was calculated by the following equation.
[반응식 1]Scheme 1
라디칼 소거활성 (%) = (ODcontrol-ODsample)/ODcontrol × 100Radical scavenging activity (%) = (ODcontrol-ODsample) / ODcontrol × 100
그리고, 목초액 유기성분이 DPPH radical을 어느 정도 억제하는지를 측정한 결과, 도 4에 도시된 바와 같이, 본 발명의 목초액 유기물은 0.1mg/㎖, 0.5mg/㎖, 1.0mg/㎖의 농도에서 라디칼 소거효과가 각각 35.6%, 68.8%, 82.4%로 측정되었다.And, as a result of measuring the extent to which the organic component of the wood vinegar inhibits DPPH radical, as shown in Figure 4, the wood vinegar organic compound of the present invention is radical scavenging effect at the concentration of 0.1mg / ㎖, 0.5mg / ㎖, 1.0mg / ㎖ Were 35.6%, 68.8%, and 82.4%, respectively.
이로부터 본 발명의 목초액 유기물은 라티칼 소거 효과가 매우 우수한 것을 알 수 있었다.From this, it was found that the wood vinegar organic matter of the present invention was very excellent in the radical scavenging effect.
상기에서 설명한 바와 같이, 본 발명에 따른 목초액의 유기물은 암을 치료하거나 동시에 돌연변이의 억제에 의해 암을 예방할 수 있고, 항균 및 항산화 효과를 활용하여 건강기능 식품에도 첨가물로 사용될 수 있는 효과가 있다.As described above, the organic matter of the wood vinegar according to the present invention can prevent cancer by treating the cancer or at the same time by inhibiting mutations, and has an effect that can be used as an additive in health foods by utilizing antibacterial and antioxidant effects.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040055842A KR100733982B1 (en) | 2004-07-19 | 2004-07-19 | Organic constituents of wood vinegar from Konara having the effects of cure and prevention of cancer, antibacterial and antioxidant |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040055842A KR100733982B1 (en) | 2004-07-19 | 2004-07-19 | Organic constituents of wood vinegar from Konara having the effects of cure and prevention of cancer, antibacterial and antioxidant |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060007104A true KR20060007104A (en) | 2006-01-24 |
KR100733982B1 KR100733982B1 (en) | 2007-06-29 |
Family
ID=37118480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040055842A KR100733982B1 (en) | 2004-07-19 | 2004-07-19 | Organic constituents of wood vinegar from Konara having the effects of cure and prevention of cancer, antibacterial and antioxidant |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100733982B1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105638737A (en) * | 2016-01-25 | 2016-06-08 | 抚顺市世纪东方生物质综合技术开发有限公司 | Mongolian oak wood vinegar extract, preparation method and application thereof and harmless insecticide |
KR101976681B1 (en) * | 2019-01-16 | 2019-05-09 | (주)세림바이오테크 | Off-flavor reducing technique for natural extracts |
WO2020204391A3 (en) * | 2019-04-02 | 2020-11-26 | Wang Sung Ho | Clinical usage of pyroligneous liquor |
JP2022508266A (en) * | 2018-11-28 | 2022-01-19 | 董福田 | Substances for treating and / or preventing tumors, as well as their design and manufacturing methods |
JP2022511445A (en) * | 2018-11-28 | 2022-01-31 | 董福田 | Substances for the treatment and / or prevention of diseases, and their design and manufacturing methods. |
EP3888665A4 (en) * | 2018-11-28 | 2022-11-16 | Futian Dong | Substance for disease treatment and/or prevention, and design method and preparation method therefor |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020030180A (en) * | 2000-10-16 | 2002-04-24 | 안용찬 | Separation process for natural anti-oxidant components from wood vinegar liquid and cosmetics containing natural anti-oxidant components using the same |
-
2004
- 2004-07-19 KR KR1020040055842A patent/KR100733982B1/en active IP Right Grant
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105638737A (en) * | 2016-01-25 | 2016-06-08 | 抚顺市世纪东方生物质综合技术开发有限公司 | Mongolian oak wood vinegar extract, preparation method and application thereof and harmless insecticide |
CN105638737B (en) * | 2016-01-25 | 2018-08-14 | 抚顺市世纪东方生物质综合技术开发有限公司 | Toothed oak wood wood vinegar extract and its preparation method and application and environmental-pollution insecticide |
JP2022508266A (en) * | 2018-11-28 | 2022-01-19 | 董福田 | Substances for treating and / or preventing tumors, as well as their design and manufacturing methods |
JP2022511445A (en) * | 2018-11-28 | 2022-01-31 | 董福田 | Substances for the treatment and / or prevention of diseases, and their design and manufacturing methods. |
EP3888681A4 (en) * | 2018-11-28 | 2022-03-02 | Futian Dong | Substance for treating and/or preventing tumors, and design method and preparation method therefor |
EP3888682A4 (en) * | 2018-11-28 | 2022-11-16 | Futian Dong | Substance for treating and/or preventing diseases, and design method and preparation method therefor |
EP3888665A4 (en) * | 2018-11-28 | 2022-11-16 | Futian Dong | Substance for disease treatment and/or prevention, and design method and preparation method therefor |
KR101976681B1 (en) * | 2019-01-16 | 2019-05-09 | (주)세림바이오테크 | Off-flavor reducing technique for natural extracts |
WO2020204391A3 (en) * | 2019-04-02 | 2020-11-26 | Wang Sung Ho | Clinical usage of pyroligneous liquor |
Also Published As
Publication number | Publication date |
---|---|
KR100733982B1 (en) | 2007-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101694913B1 (en) | Composition for improvement of learning and memory function comprising onion extract or its fraction as effective component | |
Waghulde et al. | Antioxidant activity, phenol and flavonoid contents of seeds of Punica granatum (Punicaceae) and Solanum torvum (Solanaceae) | |
Rajesh et al. | Antioxidant and antimicrobial activity of leaves of Terminalia catappa and Anacardium occidentale: A comparative study | |
KR100844185B1 (en) | The manfacturing method of fermentation artemisia tea with lactic acid | |
KR100733982B1 (en) | Organic constituents of wood vinegar from Konara having the effects of cure and prevention of cancer, antibacterial and antioxidant | |
KR101713654B1 (en) | Oral composition containing magnolia extract and phytoncide oil | |
KR101049493B1 (en) | Compositions for improving memory power and learning ability comprising extract from lepidium apefalum as active ingredient | |
KR101071684B1 (en) | Compositions for improving memory power and learning ability comprising extract from illicium verum as active ingredient | |
Radwan et al. | Seasonal Variations in Antioxidant Activity, Total Flavonoids Content, Total Phenolic Content, Antimicrobial Activity and Some Bioactive Components of Ficus carica L. in Palestine | |
Weli et al. | The antibacterial, antioxidant and anti enzymatic activities of the leaves’ crude extracts of Hyoscyamus gallagheri | |
CN112516232A (en) | Antibacterial, anti-inflammatory and antioxidant carex meyeriana extract, and preparation method and application thereof | |
Baba et al. | Toxicity study, phytochemical characterization and anti-parasitic efficacy of aqueous and ethanolic extracts of Sclerocarya birrea against Plasmodium berghei and Salmonella typhi | |
Lee et al. | Inhibition of growth and urease of Helicobacter pylori by Korean edible seaweed extracts | |
Myint et al. | Screening of phytochemicals, antioxidant and antimicrobial activities of Blumea lacera (Burm. f.) DC. Leaf and Root | |
KR20160082284A (en) | Composition comprising mastic for preventing and treating gastric diseases | |
Shonekan et al. | ANTIOXIDANT AND GLUCOSIDASE INHIBITION ACTIVITIES OF THE MUSHROOM: †œPHAEOGYROPORUS PORTENTOSUS†| |
Aremu et al. | Evaluation of leafy part of Borreria verticillata (L)(Rubiaceae) crude extracts for anti-dermatophytic properties and anti-drug resistant pathogens | |
Bouhlel et al. | Acacia salicina extracts protect against DNA damage and mutagenesis in bacteria and human lymphoblast cell K562 cultures | |
KR20130131973A (en) | Anticariogenic composition comprising extract of bark of alnus japonica (thunberg) steudel | |
KR100422094B1 (en) | A composition having an effect of curing and preventing cancer by containing a methylenechloride extract of Rumex acetosa L. | |
KR20140052580A (en) | Neuroprotective composition for comprising algae extract fucoxanthin | |
Ruth Christiya et al. | Screening of physicochemical properties and in vitro free radical scavenging activity of Delonix elata L. leaf extracts. | |
Christiya et al. | Screening of Physicochemical properties and In Vitro free radical scavenging activity of Delonix elata L. leaf extracts | |
KR101095013B1 (en) | A composition isolated from Ishige okamurae extracts having cholinesterase inhibitory activity | |
Ahmed et al. | In vitro Investigation of Thrombolytic, Membrane Stabilizing, Antidiarrhoeal and Antimicrobial Activity of Aerial Parts of Truimfetta pilosa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130410 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140417 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150417 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180423 Year of fee payment: 12 |